Although many reports suggested a crucial role of NK activities in TKI treatment responses for CML, how these BCR-ABL inhibitors modulated expressions of NK receptors had not been characterized. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.